{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:02:12Z","timestamp":1792425732143,"version":"4.5.0"},"reference-count":66,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Although immune checkpoint inhibitors (ICIs) and anti-angiogenic drugs have demonstrated effectiveness in treating advanced gastric cancer (GC), their role in neoadjuvant or conversion therapy remains uncertain. This study aimed to evaluate the efficacy and safety of combining neoadjuvant chemotherapy with anti-angiogenesis and ICIs in patients with locally advanced GC (LAGC).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this cohort study, we reviewed our prospectively maintained GC database and included individuals diagnosed with clinical stage II-III GC who received neoadjuvant therapy followed by surgery between January 2022 and August 2023. The treatment protocol combined ICIs, anti-angiogenic therapy (specifically apatinib), and chemotherapy (S-1 with oxaliplatin). A systematic approach was used to document patients\u2019 clinical and pathological characteristics, pathological findings, and survival outcomes, which were subsequently analyzed in detail.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 38 individuals met the study\u2019s inclusion criteria, with the majority (32 patients, 84.2%) having clinical stage III GC. All participants underwent surgery, resulting in a notable R0 resection rate of 97.4%. The rates of major pathological response (MPR) and pathological complete response (pCR) were 47.4% and 23.7%, respectively. Post-surgery, 36 patients (92.1%) received adjuvant chemotherapy. With a median follow-up of 22 months, ten patients experienced disease recurrence, including three who died from tumor relapse. The 1-year overall survival (OS) rate stood at 100%, and the disease-free survival (DFS) rate was 94.7%, with median OS and DFS yet to be reached. The neoadjuvant therapy regimen was generally well-tolerated, with no grade 5 treatment-related adverse events (TRAEs) reported. Only one patient experienced a grade 4 TRAE (immune-related hepatitis), while the most common grade 3 TRAEs included thrombocytopenia, elevated aminotransferase levels, and neutropenia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The combination of neoadjuvant chemotherapy, anti-angiogenic therapy, and ICIs has proven effective in treating LAGC patients, achieving high pCR rates and favorable survival outcomes while maintaining an acceptable safety profile.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1518217","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T06:34:23Z","timestamp":1738650863000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Neoadjuvant chemotherapy combined with antiangiogenic therapy and immune checkpoint inhibitors for the treatment of locally advanced gastric cancer: a real - world retrospective cohort study"],"prefix":"10.3389","volume":"16","author":[{"given":"Zhouwei","family":"Zhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaohua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruyu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohuan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanping","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanting","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhua","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zengqing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer\u00a0statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer","volume":"355","author":"Cunningham","year":"2006","journal-title":"New Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32557-1","article-title":"Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet (London England)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00541-7","article-title":"Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study","volume":"25","author":"Shitara","year":"2023","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.5908","article-title":"Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with\u00a0S-1 versus surgery alone in stage II or III gastric cancer","volume":"29","author":"Sasako","year":"2011","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61873-4","article-title":"Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial","volume":"379","author":"Bang","year":"2012","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-021-09624-5","article-title":"Outcomes of neoadjuvant chemotherapy for clinical stages 2 and 3 gastric cancer patients: analysis of timing and site of recurrence","volume":"28","author":"Nakauchi","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-019-00956-6","article-title":"Recurrence after preoperative chemotherapy and surgery for gastric adenocarcinoma: a multicenter study","volume":"22","author":"Mokadem","year":"2019","journal-title":"Gastric Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet (London England)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Sci (New York NY)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1035323","article-title":"Manipulation of the crosstalk between tumor angiogenesis and immunosuppression in the tumor microenvironment: Insight into the combination therapy of anti-angiogenesis and immune checkpoint blockade","volume":"13","author":"Zheng","year":"2022","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9030675","article-title":"Combining immune checkpoint inhibitors with anti-angiogenic agents","volume":"9","author":"Ciciola","year":"2020","journal-title":"J Clin Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.5995","article-title":"Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction","volume":"34","author":"Li","year":"2016","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30271-0","article-title":"Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial","volume":"21","author":"Kawazoe","year":"2020","journal-title":"Lancet Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03296","article-title":"Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase ib trial (REGONIVO, EPOC1603)","volume":"38","author":"Fukuoka","year":"2020","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4691","article-title":"Camrelizumab combined with chemotherapy followed by camrelizumab plus apatinib as first-line therapy for advanced gastric or gastroesophageal junction adenocarcinoma","volume":"27","author":"Peng","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B19","volume-title":"TNM classification of Malignant tumours","author":"Brierley","year":"2017"},{"key":"B20","volume-title":"AJCC cancer staging manual","author":"Amin","year":"2017"},{"key":"B21","doi-asserted-by":"publisher","first-page":"106165","DOI":"10.1016\/j.ijsu.2021.106165","article-title":"STROCSS 2021: Strengthening the reporting of cohort, cross-sectional and case-control studies in surgery","volume":"96","author":"Mathew","year":"2021","journal-title":"Int J Surg (London England)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-020-01042-y","article-title":"Japanese gastric cancer treatment guidelines 2018 (5th edition)","volume":"24","year":"2021","journal-title":"Gastric Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e3181b13ca2","article-title":"The Clavien-Dindo classification of surgical complications: five-year experience","volume":"250","author":"Clavien","year":"2009","journal-title":"Ann Surg"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer (Oxford England: 1990)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11660","article-title":"Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy","volume":"98","author":"Becker","year":"2003","journal-title":"Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-017-6078-x","article-title":"Validation of the 8th edition of the AJCC TNM staging system for gastric cancer using the national cancer database","volume":"24","author":"In","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i2.274","article-title":"Neoadjuvant chemotherapy for gastric cancer. Is it a must or a fake","volume":"24","author":"Reddavid","year":"2018","journal-title":"World J Gastroenterol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0189294","article-title":"Correlation of pathological complete response with survival after neoadjuvant chemotherapy in gastric or gastroesophageal junction cancer treated with radical surgery: A meta-analysis","volume":"13","author":"Li","year":"2018","journal-title":"PloS One"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2018.05.05","article-title":"Oxaliplatin plus S-1 or capecitabine as neoadjuvant or adjuvant chemotherapy for locally advanced gastric cancer with D2 lymphadenectomy: 5-year follow-up results of a phase II-III randomized trial","volume":"30","author":"Xue","year":"2018","journal-title":"Chin J Cancer Res = Chung-kuo yen cheng yen chiu"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1634\/theoncologist.2019-0416","article-title":"Oxaliplatin plus capecitabine in the perioperative treatment of locally advanced gastric adenocarcinoma in combination with D2 gastrectomy: NEO-CLASSIC study","volume":"24","author":"Yu","year":"2019","journal-title":"oncologist"},{"key":"B31","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1186\/s12885-018-4615-z","article-title":"Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis","volume":"18","author":"Wang","year":"2018","journal-title":"BMC Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.e16044","article-title":"Efficacy and safety of camrelizumab combined with FLOT versus FLOT alone as neoadjuvant therapy in patients with resectable locally advanced gastric and gastroesophageal junction adenocarcinoma who received D2 radical gastrectomy: Data update","volume":"40","author":"Liu","year":"2022","journal-title":"Am Soc Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"4536","DOI":"10.1200\/JCO.2020.38.15_suppl.4536","article-title":"Camrelizumab combined with FOLFOX as neoadjuvant therapy for resectable locally advanced gastric and gastroesophageal junction adenocarcinoma","volume":"38","author":"Liu","year":"2020"},{"key":"B34","doi-asserted-by":"publisher","first-page":"4001","DOI":"10.1200\/JCO.2023.41.16_suppl.4001","article-title":"Perioperative PD-1 antibody toripalimab plus SOX or XELOX chemotherapy versus SOX or XELOX alone for locally advanced gastric or gastro-oesophageal junction cancer: Results from a prospective, randomized, open-label, phase II trial","volume":"41","author":"Yuan","year":"2023","journal-title":"Am Soc Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003635","article-title":"Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study","volume":"10","author":"Jiang","year":"2022","journal-title":"J immunotherapy Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.959295","article-title":"Neoadjuvant tislelizumab and tegafur\/gimeracil\/octeracil (S-1) plus oxaliplatin in patients with locally advanced gastric or gastroesophageal junction cancer: Early results of a phase 2, single-arm trial","volume":"12","author":"Yin","year":"2022","journal-title":"Front Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-023-13143-w","article-title":"Neoadjuvant therapy with immune checkpoint inhibitors in gastric cancer: A systematic review and meta-analysis","volume":"30","author":"Li","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02758-x","article-title":"Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial","volume":"30","author":"Verschoor","year":"2024","journal-title":"Nat Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.074","article-title":"LBA73 Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC\/GEJC): Interim results of the global, phase III MATTERHORN study","volume":"34","author":"Janjigian","year":"2023","journal-title":"Ann Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2023.41.4_suppl.446","article-title":"Primary results of the ICONIC phase 2 trial of perioperative FLOT plus avelumab (FLOT-A) in operable oesophagogastric adenocarcinoma (OGA)","volume":"41","author":"Gordon","year":"2023","journal-title":"Am Soc Clin Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"New Engl J Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61719-5","article-title":"Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"383","author":"Fuchs","year":"2014","journal-title":"Lancet (London England)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.132852","article-title":"Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma","volume":"5","author":"Wood","year":"2020","journal-title":"JCI Insight"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.01.035","article-title":"Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma","volume":"66","author":"Karam","year":"2014","journal-title":"Eur Urol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.1200\/JCO.2020.38.15_suppl.4501","article-title":"Perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric adenocarcinoma (RAMSES\/FLOT7): Results of the phase II-portion\u2014A multicenter, randomized phase II\/III trial of the German AIO and Italian GOIM","volume":"38","author":"Al-Batran","year":"2020","journal-title":"J Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30043-8","article-title":"Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial","volume":"18","author":"Cunningham","year":"2017","journal-title":"Lancet Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0413-z","article-title":"Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors","volume":"17","author":"Galluzzi","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-1366","article-title":"Molecular mechanisms and future implications of VEGF\/VEGFR in cancer therapy","volume":"29","author":"Patel","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B50","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12964-022-00854-y","article-title":"Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons","volume":"20","author":"Naimi","year":"2022","journal-title":"Cell communication signaling: CCS"},{"key":"B51","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.gendis.2018.05.003","article-title":"Immunogenic effects of chemotherapy-induced tumor cell death","volume":"5","author":"Wang","year":"2018","journal-title":"Genes Dis"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112437","article-title":"Apatinib remodels the immunosuppressive tumor ecosystem of gastric cancer enhancing anti-PD-1 immunotherapy","volume":"42","author":"Luo","year":"2023","journal-title":"Cell Rep"},{"key":"B53","doi-asserted-by":"publisher","first-page":"107929","DOI":"10.1016\/j.intimp.2021.107929","article-title":"PD-1 inhibitor combined with apatinib modulate the tumor microenvironment and potentiate anti-tumor effect in mice bearing gastric cancer","volume":"99","author":"Chen","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S355687","article-title":"Efficacy and safety of sintilimab in combination with concurrent chemoradiotherapy for locally advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma (SHARED): study protocol of a prospective, multi-center, single-arm phase 2 trial","volume":"14","author":"Wei","year":"2022","journal-title":"Cancer Manage Res"},{"key":"B55","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41467-023-44309-5","article-title":"Neoadjuvant camrelizumab and apatinib combined with chemotherapy versus chemotherapy alone for locally advanced gastric cancer: a multicenter randomized phase 2 trial","volume":"15","author":"Lin","year":"2024","journal-title":"Nat Commun"},{"key":"B56","doi-asserted-by":"publisher","first-page":"e2116240","DOI":"10.1001\/jamanetworkopen.2021.16240","article-title":"Effectiveness and safety of apatinib plus chemotherapy as neoadjuvant treatment for locally advanced gastric cancer: A nonrandomized controlled trial","volume":"4","author":"Lin","year":"2021","journal-title":"JAMA network Open"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds074","article-title":"Oxaliplatin-related thrombocytopenia","volume":"23","author":"Jardim","year":"2012","journal-title":"Ann oncology: Off J Eur Soc Med Oncol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1038\/s41598-023-27824-9","article-title":"The predictive model for risk\u00a0of\u00a0chemotherapy-induced thrombocytopenia based on antineoplastic drugs for solid tumors in eastern China","volume":"13","author":"Zhou","year":"2023","journal-title":"Sci Rep"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30175-3","article-title":"Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study","volume":"6","author":"Delanoy","year":"2019","journal-title":"Lancet Haematology"},{"key":"B60","doi-asserted-by":"publisher","first-page":"111606","DOI":"10.1016\/j.intimp.2024.111606","article-title":"PD-1\/PD-L1 inhibitor-induced immune thrombocytopenia: A pharmacovigilance study and systematic review","volume":"129","author":"Moore","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.650292","article-title":"Immune checkpoint inhibitor associated hepatotoxicity in primary liver cancer versus other cancers: A systematic review and meta-analysis","volume":"11","author":"Fu","year":"2021","journal-title":"Front Oncol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/CJI.0000000000000347","article-title":"Analysis of risk factors for hepatotoxicity induced by immune checkpoint inhibitors","volume":"44","author":"Cho","year":"2021","journal-title":"J immunotherapy (Hagerstown Md: 1997)"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.v12.8","article-title":"Hepatic failure associated with immune\u00a0checkpoint inhibitors: An analysis of the Food and Drug Administration Adverse Event Reporting System database","volume":"12","author":"Xu","year":"2023","journal-title":"Cancer Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12144641","article-title":"Fulminant\u00a0liver failure after treatment with a checkpoint inhibitor for gastric cancer: A case report and review of the literature","volume":"12","author":"Dibos","year":"2023","journal-title":"J Clin Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn501113-20220216-00068","article-title":"Analysis of severe liver injury in a patient treated with oxaliplatin, capecitabine, and a PD-1 inhibitor: a case report","volume":"31","author":"Wang","year":"2023","journal-title":"Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chin J Hepatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1518217\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T06:34:28Z","timestamp":1738650868000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1518217\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,4]]},"references-count":66,"alternative-id":["10.3389\/fimmu.2025.1518217"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1518217","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,4]]},"article-number":"1518217"}}